Charles River Laboratories Inte

Charles River Laboratories International, Inc. is a global contract research organization (CRO) that provides a comprehensive portfolio of products and services to accelerate the drug discovery and development process. The company supports pharmaceutical, biotechnology, government, and academic institutions in bringing new therapies to market. Its offerings span from early-stage research through safety assessment and manufacturing support, making it a key partner in the life sciences ecosystem.

Revenue is generated through three segments: Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing Solutions (Manufacturing). DSA is the largest segment, offering toxicology, pathology, and drug metabolism services. RMS provides animal models and associated services, while Manufacturing focuses on cell and gene therapy production and microbial solutions. The company operates on a fee-for-service model, with revenue tied to project milestones and long-term contracts.

Charles River operates in the highly competitive CRO industry, facing rivals such as Labcorp Drug Development, IQVIA, and WuXi AppTec. Its competitive advantage lies in its integrated service model, spanning early discovery to clinical support, and its strong reputation for quality and regulatory compliance. The company is positioned as a mid-to-large player with a focus on innovation and expanding capabilities in biologics and cell therapy.

Its primary customers are pharmaceutical and biotechnology companies of all sizes, as well as government agencies and academic research centers. Geographically, revenue is diversified: approximately 60% from North America, 25% from Europe, and 15% from Asia-Pacific and other regions. The company's global footprint allows it to serve clients worldwide, with a significant presence in the US, UK, Canada, and Japan.

An auto-generated descriptive profile based on company data, for informational purposes only.